



KMH:elb 10/28/08 8121-82023-01 1014949

Attorney Reference Number 8121-82023-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Jacques Thilly and Christian

Vandecasserie

**Application No.** 10/584,978

**Filed:** January 25, 2007

**Confirmation No.** 2397

**For:** NOVEL DEVICE

**Examiner:** Not yet assigned

**Art Unit:** 3651

**Attorney Reference No.** 8121-82023-01

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Kevin M. Hayes

Date Mailed

11/17/8

COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

**TRANSMITTAL LETTER**

Enclosed for filing in the application referenced above are the following:

- ☒ Power of Attorney and Correspondence Address Indication Form
- ☒ Statement Under 37 CFR 3.73(b) (w/copy of assignment)
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

Kevin M. Hayes  
Registration No. 54,158

cc: Client  
Docketing



PTO/SB/81 (06-04)


Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

<b>POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM</b>	<b>Application Number</b>	10/584,978
	<b>Filing Date</b>	01/25/2007
	<b>First Named Inventor</b>	Jacques Thilly
	<b>Title</b>	Novel Device
	<b>Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	B45320

\*\*\*All previously filed Powers of Attorney are hereby revoked.\*\*\*

I hereby appoint:	
<input checked="" type="checkbox"/> <b>Practitioners associated with the Customer Numbers.</b> 24197	
Or	
<input type="checkbox"/> Practitioner(s) named below:	
Name	Registration Number
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.	
Please recognize or change the correspondence address for the above-identified application to:	
<input type="checkbox"/> The address associated with the above-mentioned Customer Number:	
Or	
<input checked="" type="checkbox"/> <b>The address associated with Customer Number 24197</b>	
Or	
<input type="checkbox"/> Firm or Individual Name:	
Address:	
Address:	
City:	State:      Zip:
Country:	
Telephone:	Fax:
I am the:	
<input type="checkbox"/> Applicant/Inventor:	
<input checked="" type="checkbox"/> Assignee or record of the entire interest. See 37 CFR 3.71.	
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)	
<b>SIGNATURE of Applicant or Assignee of Record</b>	
Signature: 	Date: 9/25/08
Name: Edward R. Gimmi	Telephone: (610) 270-4478
Title and Company: Attorney, GlaxoSmithKline Biologicals S.A.	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.	
<input type="checkbox"/> *Total of:      forms are submitted.	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/96 (12-05)

Approved for use through 7/31/2006. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT UNDER 37 CFR 3.73(b)****Applicant/Patent Owner: GlaxoSmithKline Biologicals S.A.****Application No./Patent No.: 10/584,978; Filed/Issue Date: 01/25/2007****Entitled:****GlaxoSmithKline Biologicals S.A., a corporation, states that it is:**1. ☒ the assignee of the entire right, title, and interest; or2. ☐ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is \_\_\_\_\_ % in the patent application/patent identified above by virtue of either;

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 018781, Frame 0463, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

9/25/08  
Date

Edward R. Gimmi

Printed or Typed Name

(610) 270-4478

Telephone Number

Attorney

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket No.: B45320

**ASSIGNMENT**

WHEREAS I/We, Jacques THILLY and Christian VANDECASSERIE, of Rixensart, Belgium  
have made an invention entitled:


**NOVEL DEVICE**

for which on \_\_\_\_\_ I/we executed an  
application for Letters Patent of the United States of America;

NOW, THEREFORE, in return for valuable consideration paid to me/us by  
GlaxoSmithKline Biologicals s.a. of rue de l'Institut 89, B-1330 Rixensart, Belgium  
(hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and  
intending to be legally bound, I/we do hereby assign unto the said ASSIGNEE, its  
successors and assigns, the entire right, title and interest in and to the said  
invention, said executed application, any division, continuation and continuation-in-  
part of said application and reissue applications, and all Letters Patents of the United  
States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has  
been or will be made or entered into which would conflict with this assignment and  
sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts  
and documents relating to said invention, and said Letters Patent as may be known  
and accessible to me/us, and to testify as to the same in any interference or litigation  
related thereto, and to execute further instruments (including divisional, continuation,  
continuation-in-part or reissue applications, affidavits or other instruments) required  
to apply for, obtain, maintain and enforce said application and said Letters Patent  
which may be necessary; this agreement to be binding upon my/our heirs, executors  
and administrators.

  
Inventor 1  
Jacques THILLY

Date: 31 March 05

  
Inventor 2  
Christian VANDECASSERIE

Date: 31 March 05